Our Drug Pipeline


TA-A001 is TALLC’s non-scheduled, proprietary small molecule new mechanism of action anti-inflammatory analgesic that selectively and potently activates human CB2  receptors. Synergistic with NSAIDs but lacking their negative effects on wound healing TA-A001 displays potent analgesic, anti-inflammatory effects in gold standard models of incisional surgery, uveitis and progressive vitreoretinopathy without the risks of dependency or increased intra-ocular pressure produced by opioid or corticosteroid drugs. TALLC is developing SmartCelle TA-A001 to improve the pain, inflammation and long term outcomes of corneal cross-linking keratoconus surgery, PRK and Cataract surgery


TA-A002 is a CB2/CB1 agonist with a bias for the CB1 receptor. TALLC is developing SmartCelle TA-A002 as a topical treatment for chronic back of eye diseases including glaucoma and age-related macula degeneration



TA-A003 is a commercially available COX-2 inhibitor currently marketed in tablet form only. TALLC is developing a SmartCelle formulation of TA-A003 as a topical treatment for wet age-related macular degeneration.


Phone: 514 883 3447

Email: info@tallcinc.com


TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020